Salicinium: A Herbal Cancer Treatment Method That Tricks Cancer Cells
Salicinium, a natural plant extract, is a glycome (complex sugar molecule) that enters into a metabolic reaction which shuts down the ability of the cancer cell to hide from the immune system. An active immune system can then recognize the cancer cell as abnormal and destroy it without harming any normal cells.
In 1931, German physician and scientist Otto Warburg received the Nobel Prize for proving that all cancer cells primarily use a very primitive method of producing energy from sugar. (1) It is called anaerobic metabolism or glycolysis. This is actually a form of fermentation. It takes place in the liquid part of the cell called the cytoplasm without the use of oxygen. This process is 18 times less efficient at producing a given amount of energy from a given amount of sugar than normal aerobic metabolism using oxygen.
A person forms cancer for only one reason: a lack of sufficient oxygen to a certain subset of the 210 different types of cells known to make up the human body. This is called hypoxia. There may be a thousand things that cause hypoxia, but there is no cancer cell which does not commence and live by hypoxia. To survive and keep producing energy, these cells must switch over to glycolysis alone as the source of their energy. At exactly the same time as fermentation starts, the now sickened, dysfunctional cells must also start protecting themselves from the immune system. This is also exactly what our normal muscle cells do when overworked and the oxygen level falls below a level necessary for respiration. They do this by producing a protective enzyme called alpha-N-acetylgalactosaminidase, Nagalase for short.
The Nagalase enzyme has the ability to completely shut down the localized immune macrophage cell, whose job is to destroy any cell that has been harmed or is not functioning normally. It effectively "cloaks" the cancer cells from detection by the immune system. This is the reason that someone can have a strong functioning immune system and still be growing a tumor.
Cancer cells live in a very acidic environment. The acidic environment does not create the cancer; it's the other way around. The process for this is NAD +; a coenzyme (nicotinamide adenine dinucleotide) in the cell, through an oxidation/reduction reaction attaches itself to a hydrogen atom and becomes NADH-. The hydrogen then passes out through the cell membrane by way of lactate and into the milieu of the surrounding environment. This process takes hydrogen atoms from inside the cells to the outside and is repeated over and over. A lack of hydrogen is alkaline and overabundance is acidic.
Utilizing the glycolytic pathway, when the malignant cell senses Salicinium passing by in the bloodstream, it invites it in, and very quickly another enzyme, b-glucosidase, found in abundance in fermenting cells, splits the sugar from the complex molecule. The nonglycome part of the molecule, when released, attaches to the NAD+ and disrupts the oxidation/reduction process that creates the NADH-. This causes the cell to cease production of Nagalase. (2-8)
With a stopping of the production of Nagalase, the macrophage (NK; natural killer) cells can resume their function, which was "turned off" by the Nagalase and can once again recognize the now-sick, unprotected, dysfunctional cells and dispose of them as they would any other cells at the end of their life cycle. Salicinium has simply removed the cloak, allowing the body's own natural immune response to work as it should. Since Salicinium is a complex sugar, it is harmless to any normal cell in the body because a normal cell cannot assimilate complex glycomes due to having no b-glucosidase and because Salicinium is a complexed molecule as discussed before and not a "free" glucose, it has no impact on the patients' blood sugar, making it beneficial for use in diabetics. Finger-stick glucose testing will quickly prove this important point.
The Salicinium molecule is very tiny, able to go to any place in the body that blood or other fluids go, including through barriers placed by the body for protection such as the blood--brain barrier. The molecule is so small that with each gram reaching the bloodstream, there are 2120 quintillion individual opportunities for any fermenting cell to absorb it. The daily dose is 3 grams. It is for this reason that circulating tumor cells (CTCs) and circulating stem cells (CSCs) can be reduced in as little as 5 days and control can be gained in as little as three weeks of IV and oral treatment.
Salicinium has a half-life of approximately 24 hours and is administered by intravenous (IV) infusion 5 days per week for 3 consecutive weeks to start the therapy. Orasal is the encapsulated form started orally with the initial IV start-up. It has never had a known side effect other than those functions allowed or caused by the immune system, such as chills, localized fever in the area of the tumor, or swelling of the tumor being filled with lymphatic fluids to carry away the necrotizing tissue; and most of the time patients will find relief from pain enough to lower their intake of pain meds.
Testing for effectiveness of Salicinium has been performed by RGCC (Research Genetic Cancer Center) Laboratory in Greece. Its testing platform is known as "ex vivo." Ex vivo (Latin: "out of living") means that which takes place outside an organism. In science, ex vivo refers to experiments or measurements done in or on tissues, in this case CTCs and CSCs in an artificial environment outside the organism with the minimum alteration of natural conditions.
RGCC uses powerful sorters and flow cytometers as well as negative selection based interrogation to separate and harvest all the CTCs and CSCs from a single blood sample. It then expands the population of these cells in cell culture while managing to keep intact both the genotype and phenotype of the cells.
The expanded cell population is then tested for sensitivity/resistance against 50 natural substances and 43 chemotherapeutic agents. The purpose of the test is to single out the best possible treatment options for each individual patient, and it is of note that the results found in this form of testing prove far more efficacious in vivo. (9) According to Larry Weisenthal, MD, PhD, patients treated with drugs active in these assays have, on average, a 7-fold greater chance of benefiting from treatment with drugs showing good results in the assays compared with treatment with drugs showing poor results in the assays. (10) Results of this testing using Salicinium can be found in the box below.
A study was also performed by the Biofocus Lab in Germany comparing NK-cell activity before and after dosing with Salicinium. The test is performed in much the same way as the lab in Greece but instead for the purpose of seeing what enhances the NK cells the most in each patient. (11)
Immune-Stimulative Effect of Salicinium on Immune-Cells from Cancer Patients
Dr. Lothar Prix, Biofocus GmbH, Recklinghausen, Germany
Immune cells were obtained from blood samples of cancer patients. The capability of these immune cells to kill tumor cells in vitro was determined by using a cellular NK test (Neri et al. Clin Diagn Lab Immunol. 2001 November;8:1131-1135). The basal killing activity was compared with the killing activity after treatment of the immune cells with Salicinium.
It should be noted that by leaving numbers 4 and 5 out as controls, then adding the additional percentage of increases, you would arrive at a 29.9% average increase in killer cell activity. Considering the RGCC apoptosis average of 24%, you can quickly see how Salicinium does these opposite activities both at the same time, the immune system increases as the cancer cells die, both at about the same rate due to Nagalase enzyme destruction.
We have been more than pleased with this new adjunct to our treatment program. It is exciting to see our patients improve and prosper in health.
* One 59-year-old Caucasian female was treated for ovarian cancer in February 2011 with our old protocol using IPT and oxidative therapies, including high-dose IV vitamin C. She did very well for almost 2 years until her CA-125 started rising in October 2012. She came back to our clinic for retreatment. In December 2012, her initial Nagalase level was 2.6 U (nmol/min/mg; normal range is 0.32-0.95). She is doing very well, and as of February 2012, her Nagalase level had dropped to 2.2. In that same time frame her CA-125 dropped from 81.5 U (normal is 0-34) to 50. She is continuing on an oral protocol at home using oral Salicinium (Orasal).
* A 55-year-old Caucasian female who worked at the Nevada nuclear test site presented to our clinic in November 2012 with a recurrent squamous cell cancer of the tongue. Her initial Nagalase level at that time was 1.20. Since being on the initial IV Salicinium protocol, followed by Orasal, her latest Nagalase as of February 27 was 0.87 U. She continues to improve.
* 60-year-old Caucasian male with prostate cancer spread to the lymph nodes, pelvis, and spine. His PSA in August 2012 was 310 (normal 0-4). He was bedridden and in so much pain that he could barely get out of bed. His doctor at home wanted to put him on hospice.
He came to Reno and started the Salicinium protocol on February 4. His initial Nagalase level was 1.90. After his initial 3-week treatment period, he was on a home protocol and only recently returned for some IV treatments. His PSA on May 15 was 1.39. After his treatment (including IPT with 10% chemo drugs), he went running for 1 1/2 hours! One June 21, his second Nagalase was 1.70 (down from 1.90).
* 65-year-old female treated for breast cancer in December 2011 without Salicinium. Initially successful but had a recurrence and in July 2012, her initial Nagalase was 2.40 (0.32-0.95). She started on Orasal protocol in November 2012. She came to Reno for 3 weeks of the IV Salicinium protocol, including IPT, in April 2013. Her second Nagalase that same month was 1.70. She continues to do very well (riding motorcycles with her husband!), and we will repeat her Nagalase next month.
* 56-year-old male started treatment for bladder cancer with IV and oral Salicinium protocol (including IPT) since March 4, 2013. Initial Nagalase at that time was 2.80. He continues to do well (playing golf and softball). Most recent Nagalase (May 15, 2013) was 2.40.
Salicinium is showing itself to be a great step forward in the search for a new, nontoxic, effective therapeutic in the ongoing fight to defeat cancer.
RESEARCH GENETICS CANCER CENTER CHEMO SENSITIVITY TESTING JAN--APRIL 2012
250 Worldwide Patient Samples
21 Forms of Cancer
All Stage III or Stage IV
87% Response in 250 Patients
24% Apoptosis on Average
*** All measurements taken after single dose of Salicinium ***
(1.) Warburg O, Posener K, Nogelein E. Ueber den Stoffwechsel der Tumoren; Biochemische zeitschrift Vol. 152. 1924:319-344. Reprinted in English in Warburg O. On Metabolism of Tumor. London; Constable; 1930.
(2.) Korbelik M, VR Naraparaju, N Yamamoto. The value of serum alpha-N-acetylgalactosaminidase measurement for the assessment of tumour response to radio- and Photodynamic therapy. Br J Cancer, 1998;77:1009-1014.
(3.) Reddi Al. et. al. Serum alpha-N-acetylgalactosaminidase is associated with diagnosis/prognosis of patients with squamous cell carcinoma of the uterine cervix. Cancer Lett. 2000;158:61-64.
(4.) Yamamoto N, Urade M. Pathogenic, significance of alpha-N-acetylgalactosaminidase activity found in the hemagglutinin of influenza virus. Microbes Infect, 2005;7:674-681.
(5.) Yamamoto N. Pathogenic significance of alpha-N-acetylgalactosaminidase activity found in the envelope glycoprotein gpl60 of human immunodeficiency virus Type 1. AIDS Res Hum Retroviruses. 2006;22:262-271.
(6.) Yamamoto N, Suyama H, Yamamoto N. Immunotherapy for prostate cancer with Gc protein-derived macrophage activating factor (GcMAF). Transl Oncol. 2008;1:65-72.
(7.) Yamamoto N et al. Therapeutic efficacy of vitamin D3-binding protein-derived macrophage activating factor for prostate, breast and colon cancers. Cancer Res Proc. 1997;38:31.
(8.) Yamamoto et al. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res. 1996:56:2827-2831.
(9.) TU-Profile Plus. See http://www.rgcc-genlab.com/?lests.
(10.) Frequently asked questions [Web page]. The Human Tumor Assay Journal.
(11.) See Biofocus Labs: www.biofocus.de/PDF/Onkologie/BF_111_Brochure_M-Oncology.pdf.
by Robert A. Eslinger, DO, HMD
Robert Eslinger, or Doctor Bob, as we fondly call him, finished his formal medical training in 1978. He has been in clinical practice for over 30 years. He is certified in family practice, osteopathic manipulation, and homeopathy.
For 13 years before coming to Reno, he was the medical director of the Medical Center in Cascade, Idaho. Before concentrating in the area of alternative/integrative medicine, Dr. Eslinger developed a broad background in traditional medical disciplines. Everything from being stationed on a remote Indian reservation in the Public Health Service to private practice and years of working in clinics and ERs has set him on a lifelong quest to find what works for his patients.
He presently focuses on a specialty in the field known as biological medicine, which combines classical treatments with modern technology.
Dr. Bob was appointed by the governor in November 2008 to it on the Board of Homeopathic Medical Examiners for the state of Nevada.
Dr. Bob is a compassionate physician who takes time to listen to his patients' needs. He offers an abundance of life experience to his practice at Reno Integrative Medical Center, 6110 Plumas St., Ste. B, Reno, Nevada 89519; 775-829-1009; www.renointegrativemedicalcenter.com.